Karyopharm taps Amgen, Pfizer veteran as CEO

Oncology-focused Karyopharm Therapeutics has a new CEO and president: Richard Paulson, who brings with him a collective 25 years of leadership experience at Pfizer, Amgen and Ipsen North America. Paulson is tasked with commercializing Karyopharm's cancer drugs, one of which has been approved by the U.S. Food and Drug Administration for the blood cancer multiple myeloma as well as diffuse large B-cell lymphoma. Karyopharm (Nasdaq: KPTI) is currently testing the same drug, an oral treatment called…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news